ONCY Oncolytics Biotech, Inc.

$ONCY keep trying not-able-x, but everyone sees through your lies admitted PR firm paid pumper.

$ONCY I believe the MMs achieved getting there remaining shares in the low 40s ..... think they are ready to reverse the trend .... next few days would validate that

$ONCY more b-s from the admitted PR firm paid pumper, trying to tell investors that Oncy intentionally wasted investors time (30 years) and money (heavy dilution and R/S) just to get to this point...a point where Oncy still can't attract a partnership (just collaborations), hasn't proven efficacy and hasn't achieved any shareholder value.

$ONCY While the MMs were playing the amateurs like a fiddle days ago and I had to put up with fear mongering ... I read the playbook and bought more to average down to 84c

$ONCY upcoming Catalyst, buy while low and average down!! IMO 1. Patent extensions and renewals 2. Goblet Data 3.CRC data end of the year 4.Partner Announcement The Nasdaq Compliance isnt until mid January and we will surrely be over $1. Market Makers are shorting this due to an assumption of ATM covering their short, I would imagine we will be over 10 mill shorts once that's updated, 10 days to cover. Remember managment isnt getting paid like before, so quarterly burn rate is extremly low. Want to be diluted??? Sell your shares at these prices, want the price to go up? Buy into the MM short, change the agorithims. Not Investing advice just hopeful that JK pulls thru!

$ONCY I believe - now is the time to Double Down and Buy more. This Drug ROCKS in four(4)major cancer lines: Breast, Colon, Anal-Rectal SCCa & freakin Pancreatic Cancer!! Pelareorep breaks the cancer/tumors’ defense mechanisms allowing the immune system to “see” and process the tumors’ antigens in combination with checkpoint inhibitors resulting in a synergistic effect. Ironically, the longer the immune system can “see”& process the cancers heterogenous population of tumor cell antigens, the more robust an immune response!! Hence, a delay to resection is being demonstrated by longer treatment periods in various cancers including breast and colon cancers. In summary: the synergistic combination of Pelareorep + checkpoint inhibitors is Novel and is resulting in a marked improvement in both cancer DFS and OS. This company and Drug ROCKS - it’s only the beginning and ONCY will most likely be bought out by BP!! Patience is the transfer of wealth is from the impatient to the patient!

$ONCY It clear that whatever they say or have, it is not of the interest of BPs, and that is reflected in the sp. 28 years diluting with no drug in the market says it all. This company has shown time and again to be a long history of failures. Just common sense. Without the interest of a BP partner, this company is done. No RS will allow them to go on by themselves except if it is just to keep filling their pockets as long as they can at the expense of shareholders.

$ONCY this has been the most aggressive I’ve ever seen the shorters! I can’t wait for the day that there is a halt and this company is sold for even $500 mill to $4BILL. The pain that you have caused some of the Longs needs to be paid back fairly!

$ONCY the PR firm paid pumper not-able-x ( or YFuser or Noteable) is in a hissy fit panic trying to change the narrative to this "failed to deliver" conspiracy theory. Grow up kid.

$ONCY Oncolytics Biotech® Secures Patent Protection to Late 2040s and Provides Intellectual Property Portfolio Update

$ONCY The ONCY LYING BASHERS are again conflating the truth. There are NO PAID PUMPERS ON THE ONCY MESSAGE BOARDS. What there is are PAID ONCY BASHERS like the one who keeps conflating the truth.

$ONCY The naked shorts have been controlling this stock for a year now but I think their time is running out....a partnership will cause panic in their ranks ...and it is on the near horizon...JK creating a shield around the IP

$ONCY those short at their peril. $ONCY is one announcement away from crushing. i get it, biotechs are always needing cash but this one has too many connections to Big Pharma. I would love to see CEO pull a deal with one. Pela is showing real promise. Just a small partnership to start would be the ramp

$ONCY Just look at the data, interim results - all results - to date, FDA responses to date. 11 years invested and still 100% behind the company.

$ONCY Interesting and unexpected ONCY PR this morning…After method of use patent and crc data this will fly!!!

$ONCY Revolution medicines would be an ideal partner for us. 4 billion in cash our treatment would synergize nicely eith theirs.

$ONCY Nice attacke today! Final drive down before end of the month news! Don’t be caught in stop sale raid, 1.4 mill shares hit today

$ONCY Key Growth Drivers & Clinical Catalysts FDA Milestones & Fast Track Status: The FDA granted Fast Track Designation for its flagship candidate, pelareorep, in second-line anal cancer. Additionally, Oncolytics reached alignment with the FDA on a registrational trial path for second-line RAS-mutant MSS colorectal cancer. Long Patent Runway: Secured extended U.S. patents protecting the commercial manufacturing of pelareorep through 2044, securing potential long-term intellectual property rights. Wall Street Price Targets: Analyst consensus targets range from $3.00 to $5.50+, reflecting significant theoretical upside……..

$ONCY When a publicly traded company accelerates or prepares for a large block of insider options to vest in a few months, it is typically setting the stage for major corporate transitions, tax planning, or employee retention strategies. Here is what is usually "in the works" behind the scenes when this happens: 1. Preparing for a Corporate Event • A Company Sale or Merger: If a company is about to be acquired, it will often accelerate the vesting of insider options so employees can cash out or convert their options into the acquiring company's stock before the deal closes.

$ONCY Big Pharma buys to expand. Because pelareorep acts as a universal backbone, it is precisely the asset a single-franchise pharma titan needs to dismantle their own portfolio limitations, allowing them to rapidly scale a solitary drug into a multi-indication, dominant oncology ecosystem. (ERGO Checkpoint inhibitors, RAS inhibitor and immunotherapy possessing companies become strong potential ONCY acquirers)